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Osteopontin splice variants are differential
predictors of breast cancer treatment
responses
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Abstract
Background: Osteopontin is a marker for breast cancer progression, which in previous studies has also been
associated with resistance to certain anti-cancer therapies. It is not known which splice variants may mediate
treatment resistance.
Methods: Here we analyze the association of osteopontin variant expression before treatment, differentiated
according to immunohistochemistry with antibodies to exon 4 and to the osteopontin-c splice junction
respectively, with the ensuing therapy responses in 119 Polish breast cancer patients who presented between
1995 and 2008.
Results: We found from Cox hazard models, logrank test and Wilcoxon test that osteopontin exon 4 was associated
with a favorable response to tamoxifen, but a poor response to chemotherapy with CMF (cyclophosphamide,
methotrexate, fluorouracil). Osteopontin-c is prognostic, but falls short of being a significant predictor for sensitivity
to treatment.
Conclusions: The addition of osteopontin splice variant immunohistochemistry to standard pathology work-ups has
the potential to aid decision making in breast cancer treatment.
Keywords: Tumor progression marker, Immunohistochemistry, Breast cancer, Chemotherapy, Hormone therapy,
Radiation therapy
Background
Biomarkers are important for guiding the diagnosis and
treatment of cancer. Two broad groups comprise prognos-
tic markers and predictive markers. Prognostic markers
allow forecasts regarding the natural course of the disease.
They differentiate between patients likely to have a good
versus a poor outcome. By contrast, predictive markers
provide upfront information regarding how likely a patient
is to benefit from a specific treatment, and hence may
guide the choice from available therapies. Anticipating
treatment response or risk of treatment resistance is a
critical need in cancer care. Relevant predictive markers
mostly belong to the groups of drug targets, molecules
associated with drug transport or metabolism, and
regulators of apoptosis or DNA repair. As such, they
are mechanistically involved in the drug response. In
addition, because highly aggressive tumors are generally
more difficult to manage than less aggressive ones,
some prognostic indicators may also have predictive
properties.
In the histopathologic assessment of breast cancer, the
standard markers ER, PR, and HER2 identify drug tar-
gets, as ER-positive tumors are candidates for anti-
estrogen treatment whereas HER2-positive tumors are
candidates for treatment with trastuzumab. Further,
the absence of all three marker molecules defines triple-
negative breast cancers, which have a poor prognosis and
limited treatment options. There is a lack of more refined
predictive markers for treatment success in the disease.
In breast cancer, osteopontin is a biomarker for aggres-
siveness and for prognosis. Further, it has been described
as a marker for treatment responses. Osteopontin causes
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breast cancer resistance to cyclophosphamide [1], doxo-
rubicin [2–4], paclitaxel [4] and cisplatin [4] through its
anti-apoptotic properties or through the upregulation of
drug exporters. Its levels also are an indicator for progres-
sion under anastrozole [5]. According to two studies in a
breast cancer model cell line, the suppression of osteopon-
tin gene expression can enhance radiosensitivity and affect
cell apoptosis, suggesting that the molecule may be a tar-
get for the improvement of radiotherapy [6, 7]. In all these
cases, pan-osteopontin was measured. Osteopontin is
subject to alternative splicing in cancer, and it is not
known which splice form is responsible for conveying
resistance to which specific treatment. The variant
forms are distinguishable by antibodies to exon 4, recog-
nizing osteopontin-a and osteopontin-b, or to the splice
junction of osteopontin-c respectively. Here we test the
association of osteopontin splice variants, expressed in the
growths at the onset of cancer therapy, with the ensuing
response to specific treatments.
Methods
Patients
This study contained 119 patients from Poland who pre-
sented between 1995 and 2008 (allowing the assessment
of 5-year survival). All cases refer to invasive ductal car-
cinoma, grades 1, 2 and 3, with subtypes including few
mucinous and tubular carcinomas. Information about
the patients was received from the Department of General
and Oncological Surgery, Wroclaw and from the Division
of Oncological Surgery, Walbrzych, Poland. The inclusion
criteria were size of tumor not larger than 50 mm, and no
adjuvant chemotherapy at the time of immunohisto-
chemistry. For all patients, who met these criteria, par-
affin blocks were available for evaluation. The data
comprised also information about pathological TNM
(pTNM), BRCA1 status, HER2, ER and PR status, and
family history (other cases of invasive breast carcinoma
in the family). Ensuing treatment constituted combina-
tions of 1. hormone therapy with tamoxifen; 2. chemo-
therapy with CMF (cyclophosphamide, methotrexate,
fluorouracil) 6 courses every 28 days; 3. chemotherapy
with AC (cyclophosphamide, doxorubicin) 4 courses every
21 days plus CMF 6 courses every 28 days; 4. radiotherapy
to the chest (50 Gy; Mon-Fri 2 Gy) 5. radiotherapy to
chest and axilla (50 Gy; Mon-Fri 2 Gy).
Immunohistochemistry
For each antibody a formalin-fixed and paraffin-embedded
biopsy specimen from cancer tissue was cut on a micro-
tome in 5 μm slices. The antibodies used in this study, after
blocking in 2 % donkey serum, were anti-hOPNc IgY
(Gallus Immunotech), and LF161 (Larry Fisher). The IgY
antibody recognizes the osteopontin-c splice junction
and detects the molecule in immunohistochemistry. It
was diluted 1:500 to 1:700. The polyclonal rabbit anti-
body LF161 for staining selectively exon 4 (present in
osteopontin-a and -b) was used at 1:1000. For each
antibody, the tissues were scored for intensity (maximum
Table 1 Patient characteristics
n %










grade 1 36 30.3
2 65 54.6
3 18 15.1
Her2 low 69 58.0
high 29 24.4
undefined 21 17.6
PR - 64 53.8
+ 54 45.4
undefined 1 0.8
ER - 59 49.6
+ 59 49.6
undefined 1 0.8
BRCA-1 wild type 52 43.7
mutant 26 21.8
undefined 41 34.5
familial no 44 37.0
yes 40 33.6
undefined 35 29.4
chemotherapy AC 4 courses every 21 days, CMF 6 courses
every 28 days
34 28.6




chest (50 Gy; Mon-Fri 2 Gy) 41 34.5






The patient populations are described according to diverse clinical variables.
CMF cyclophosphamide, methotrexate, fluorouracil, AC cyclophosphamide,
doxorubicin
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intensity of the sample 0, 1, 2, or 3) and percent positivity
(0, 1, 2, or 3), separately for nuclei and cytoplasm. The in-
tensity of staining in immunohistochemistry was evaluated
as previously described [8] and the classification criteria of
intensity followed a published source [9]. The score was
given as 0 points if no staining was observed, 1 for weak,
2 for moderate and 3 points for strong staining. Points
were assigned to each case by two pathologists who inde-
pendently evaluated all microscopic slides and in the rare
cases of discrepant initial scores, a final score was agreed
on after discussion [8].
Statistics
All statistical analyses were performed using SAS (North
Carolina, USA). Correlations between osteopontin-c and
clinicopathological variables were assessed with Pearson’s
correlation test. Correlation coefficients of 0.1 to 0.3 are
considered weak, 0.4-0.6 is moderate, and 0.7-0.9 is strong
correlation. A p-value of 0.05 or lower indicates statistical
significance. The primary methods for addressing the
study purposes were Cox hazard models, logistic regres-
sion models, and the nonparametric Wilcoxon test. Odds
ratios estimate the odds of death for a one-unit increase in
the independent variable. Unadjusted odds ratios and
95 % confidence intervals were calculated to investigate
the effects of the components of pathological scores on
the odds of death. For survival under hormone therapy
or chemotherapy, the biomarkers osteopontin-exon-4
and osteopontin-c were also analyzed in a multiple re-
gression framework to adjust the effect for other covar-
iates. Each model contained either osteopontin-exon-4
or osteopontin-c and each other biomarker (tumor size,
lymph node involvement, grade, HER2, Progesterone
Receptor, Estrogen Receptor, or BRCA1), added one-at-
a-time. Cox hazard ratios, p-values, and Aikaike Infor-
mation Criterion (AIC) were used.
Results
Patient characteristics
Of 119 patients, 46 women (39 %) died from breast
cancer within 5 years while 73 women (61 %) were alive
after this observation period. The average age at the
time of immunohistochemistry was 53 years for non-
survivors and 53 years for survivors. All patients, com-
prising both subgroups, underwent surgery consisting
of either modified radical mastectomy with axillary
dissection, or conservative breast surgery with axillary
Table 2 Marker correlations
Exon 4 cyt.per. Exon 4 cyt.int. OPNc nucl.per. OPNc nucl.int. Tumor grade
exon 4 Pearson Correlation 1 0.69115 0.41194 0.53769 0.10199
cyt.per. p-value <0.0001 <0.0001 <0.0001 0.2697
exon 4 Pearson Correlation 1 0.31522 0.50491 0.21883
cyt.int. p-value 0.0005 <0.0001 0.0168
OPNc Pearson Correlation 1 0.6636 0.0679
nucl.per. p-value <0.0001 0.4631
OPNc Pearson Correlation 1 0.08674
nucl.int. p-value 0.3483
tumor grade Pearson Correlation 1
The table shows Pearson correlation coefficients and p-values for pairwise comparison of the histopathologic markers (osteopontin-c staining intensity,
osteopontin-c percent positivity, exon 4 staining intensity, exon 4 percent positivity) and tumor grade. Statistical significance is indicated by underlining, moderate
correlation is shown in bold
Table 3 Marker correlations
Parametric (lognormal) Logrank Wilcoxon
χ2 p-value χ2 p-value χ2 p-value
exon 4 intensity 4.82 0.0281 9.8692 0.0197 16.3818 0.0009
exon 4 high/low 7.9144 0.0049 15.5494 <0.0001
OPNc intensity 7.24 <0.0001 16.9014 0.0007 27.5348 <0.0001
OPNc high/low 2.1234 0.1438 6.4847 0.0109
tumor grade 7.63 0.0057 11.392 0.0098 9.5087 0.0232
Quantitative multivariable analysis and non-parametric tests for the prediction of survival by the markers under study (osteopontin-c, exon 4, tumor grade). Used
were either the staining levels 0,1,2,3 (intensity) or the combination of 2 and 3 versus 0 and 1 (high/low) under various model assumptions. Underlined p-values
are considered significant (p < 0.05)
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lymph node dissection and post-operative adjuvant
therapy (Table 1).
Immunohistochemistry
The anti-Osteopontin-exon-4 antibody, which recognizes
osteopontin-a and -b, stained selectively the cytoplasm.
Most tumors displayed osteopontin-c predominantly in
their nuclei. The markers correlated moderately between
each other (OPNc nuclear intensity, OPNc nuclear percent
positivity, exon 4 cytoplasmic intensity, exon 4 cytoplasmic
percent positivity), but in contrast to earlier studies they did
not correlate with grade (Table 2). Analysis for the associ-
ation with survival by the markers under investigation
(osteopontin-c, exon 4, tumor grade) reflected them as
prognostic for outcome. In addition to analyzing the indica-
tors in their original scale, we dichotomized the immuno-
histochemical biomarkers into low (0–1) or high (2–3).
Only the logrank test for dichotomized osteopontin-c fell
short of corroborating significance (Table 3).
Cancer treatment
The patients were subjected to various combinations of
hormone treatment, chemotherapy, and radiation. Hor-
mone treatment was tamoxifen. Chemotherapy comprised
one of two regimens, CMF (cyclophosphamide, metho-
trexate, fluorouracil 6 courses every 28 days) or AC/CMF
(cyclophosphamide, doxorubicin, 4 courses every 21 days
plus CMF 6 courses every 28 days). Radiotherapy was
given either to the chest (50 Gy; Mon-Fri 2 Gy) or to chest
and axilla (50 Gy; Mon-Fri 2 Gy). Except for hormone
therapy, survival after treatment (chemotherapy yes/no,
radiation therapy yes/no) was shorter than survival with-
out treatment. This reflects that more comprehensive
therapy was given to patients with more aggressive can-
cers, which are inherently associated with poor prognoses
for survival (Table 4).
Osteopontin variants and specific treatment regimens
Tamoxifen is a selective estrogen receptor modulator
that is used for the treatment of both early and advanced
ER+ (estrogen receptor positive) breast cancers in pre-
and post-menopausal women. Kaplan-Meier curves (Fig. 1)
suggested a moderate survival benefit from treatment.
When comparing hormone-treated to non-hormone-
treated patients, low-grade cancers (grade 1) responded
better to treatment than high-grade cancers (grade 2–3). In
contrast, patients with high intensity staining (2–3) of exon
4 or osteopontin-c responded better to hormone therapy
than those with low intensity staining (0–1) of these
markers, as judged by a divergence with time between the
hormone-treated and the non-hormone-treated patient
groups at high marker intensity, but much less at low
marker intensity.
For the analysis of chemotherapy responses, the com-
parison to the non-chemotherapy treated group was not
meaningful, because the survival of the treated group
was lower, which is not reflecting harm caused by the
treatment but indicates the circumstance that chemo-
therapy was given to patients with aggressive tumors
and poor prognoses. The survival curves of patients
undergoing chemotherapy (Fig. 2), when distinguished
according to low (0–1) versus high (2–3) immunohisto-
chemical markers, confirm the poor survival prognosis
associated with exon 4 and osteopontin-c [8], particu-
larly reflected in a higher rate of patient deaths between
2 and 6 years after diagnosis in the high intensity group
of each marker. Of note, the survival difference between
exon 4 high and low appeared to be larger than between
osteopontin-c high and low, implying the possibility that
the marker could also be predictive of a poor chemo-
therapy response.
The Kaplan Meier survival curves of patients undergo-
ing radiation treatment, distinguished according to low
(0–1) versus high (2–3) immunohistochemical markers,
Table 4 Survival under treatment
Years of survival
Treatment Mean std n
hormone no (all subgroups) 6.48 3.96 54
hormone yes (all subgroups) 7.44 4.35 64
hormone alone 9.89 2.00 18
hormone and chemo 6.63 4.38 16
hormone and radiation 5.10 4.63 10
hormone, chemo, radiation 7.10 4.84 21
chemo no (all subgroups) 8.30 3.79 30
chemo yes (all subgroups) 6.57 4.22 89
chemo alone 7.92 4.57 13
chemo and hormone 6.63 4.38 16
chemo and radiation 5.82 3.66 39
chemo, hormone, radiation 7.10 4.84 21
chemo (CMF 6 courses every 28 days) 6.27 4.36 55
chemo (AC 4 courses every 21 days,
CMF 6 courses every 28 days)
7.06 4.00 34
radiation no (all subgroups) 8.23 3.90 47
radiation yes (all subgroups) 6.21 4.17 72
radiotherapy alone 10.00 1.41 2
radiation and hormone 5.10 4.63 10
radiation and chemo 5.82 3.66 39
radiation, chemo, hormone 7.10 4.84 21
Shown are mean survival times in years (mean), standard deviation (std), and
number of cases (n) consecutive to the various combinations of treatment.
When censored for 13-year survivors (who may be alive beyond 13 years), the
mean survival of patients under hormone treatment is 6.423 years with standard
error 0.5274, compared to survival under no hormone treatment of 7.262 years
and standard error 0.5077
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again confirm the poor survival associated with exon 4
and osteopontin-c. Although the curves converge after
about 10 years, during 2–6 years substantially more pa-
tients die in the high marker intensity groups than in
the low marker intensity groups (Fig. 3).
Osteopontin variants as predictive markers
The above findings (reduced survival of high versus low
exon 4 and osteopontin-c under chemotherapy or radi-
ation therapy) can be interpreted as poor therapy responses
only if they are a) significant and b) distinct from the over-
all prognostic nature of these markers, as previously re-
ported [8, 10, 11]. The seemingly favorable survival of high
versus low exon 4 and osteopontin-c under hormone ther-
apy is distinct from the prognostic characteristic, but re-
quires testing for significance [12].
Cox hazard ratios (Table 5) showed that the staining
intensity for osteopontin exon 4 was negatively corre-
lated with survival in the non-hormone treated group,
but not in the hormone treated group. This is consistent
with a favorable response to tamoxifen associated with
the presence of osteopontin exon 4. By contrast, osteo-
pontin exon 4 was associated with a poor response to
chemotherapy according to reduced survival by high
level expressors in the treated group, but not in the non-
chemotherapy treated group. CMF (not AC/CMF) was
the regimen, the efficacy of which was compromised by
high osteopontin exon 4. Because a supremum test indi-
cated low confidence in the proportionality assumption,
we sought to independently corroborate the analysis
using the logrank and Wilcoxon tests (Table 6). According
to all 3 tests, exon 4 is predictive of resistance to chemo-
therapy with CMF (as judged by significantly worse sur-
vival of the high marker intensity group), but not with
AC/CMF. According to Cox hazard ratios and logrank
test, exon 4 is a predictor of a favorable response to hor-
mone therapy (the significantly worse survival associated
with high marker intensity in the non-hormone treated
group is lost under hormone therapy with tamoxifen).
Although a similar predictive potential (for a favorable
Fig. 1 Kaplan-Meier survival curves for patients undergoing hormone therapy. Survival of patients under hormone treatment, distinguished according
to low (levels 0–1) versus high (levels 2–3) osteopontin-c staining (top left), low versus high osteopontin-exon 4 staining (top right), or low (1) versus
high (2–3) tumor grade (bottom left). The overall survival of patients receiving hormone treatment versus not receiving hormone treatment is shown
for comparison on the bottom right. Untreated subgroups are displayed in black, treated subgroups in gray, low marker levels are shown as circles,
high marker levels as triangles. The x-axis indicates years since diagnosis, the y-axis reflects % surviving patients
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response to hormone therapy) is implied for osteopontin-c,
the p-values for the Cox and logrank tests in the “hormone
no” group fall just short of statistical significance.
To assess whether the prediction of treatment responses
can be strengthened when additional readouts are con-
sidered, we performed multivariate analysis. For sur-
vival with or without hormone therapy, exon 4 staining
or osteopontin-c staining were analyzed as predictors
in conjunction with other covariates (Table 7). Whereas
osteopontin-c did not improve as a predictor, the com-
bination of high exon 4 intensity plus high tumor grade
worsened the prognosis without hormone therapy (exon 4
alone hazard ratio 0.503, p-value 0.016; with grade 0.450,
0.007), but maintains the favorable prognosis under treat-
ment (exon 4 alone 0.657, 0.131; with grade 0.763, 0.352).
Hazard ratios and p-values for survival under CMF chemo-
therapy showed improvement for the prediction with the
combination of exon 4 intensity plus HER2 (0.398, 0.009),
compared to exon 4 intensity alone (0.524, 0.019). Low
HER2 and high staining intensity for osteopontin exon 4
increase the likelihood for resistance to CMF chemotherapy
(Table 8).
Discussion
In this study, we have identified osteopontin exon 4 as a
predictor for a favorable treatment response to tamoxi-
fen (the staining intensity is negatively correlated with
survival in the non-hormone treated group, but not in the
hormone treated group), but for resistance to chemother-
apy with CMF (high level expressors have reduced survival
in the treated group, but not in the non-treated group).
The combination of high staining for osteopontin exon
4 with HER2 negative status appears to increase the
likelihood for chemotherapy resistance. By contrast,
osteopontin-c is prognostic, but may not be predictive
for the therapeutic regimens applied here. Notably,
while osteopontin-c is not a predictor of survival in the
hormone treated group, a trend for it to be negatively
associated with survival time in the non-hormone
treated group fell just short of indicating significance by
Cox hazard ratio (p = 0.096) and logrank test (p = 0.066),
while significance was attained with the Wilcoxon test
(p = 0.021). Nevertheless, in multivariate analysis no im-
provement was achieved for prediction with osteopontin-c.
It is therefore more likely that a favorable response to
Fig. 2 Kaplan-Meier survival curves for patients undergoing
chemotherapy. Survival of patients under chemotherapy, distinguished
according to low (0–1, diamonds) versus high (2–3, triangles)
immunohistochemical markers. Shown are Kaplan Meier curves for
osteopontin-c (top panel) or exon 4 (middle panel). For comparison,
the survival of all patients treated (gray markers) or not treated (black
markers) with chemotherapy is displayed (bottom panel). The x-axis
indicates years since diagnosis, the y-axis reflects % surviving patients
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hormone therapy is encoded in an osteopontin-a specific
domain than in a common domain of osteopontin. The
resistance to chemotherapy is selective to exon 4. As
osteopontin-b is barely expressed in breast cancer and
the protein is rapidly degraded [13], it is implied that
osteopontin-a is the splice form responsible for resist-
ance to chemotherapy.
The favorable response to anti-estrogens by breast
cancers with high osteopontin-a levels may reflect the
property of the osteopontin gene as a sentinel for estrogen
responsiveness in mammary cells. Although an estrogen-
response element is not present in the promoter, there are
7 steroid factor-response element-like sequences in this
region. Expression may be induced by estrogen via ERRα
in a context-dependent manner [14, 15]. Tumors with
high levels of osteopontin-a probably are highly sensitive
to estrogen signals (mediated through ER or through
ERR), and therefore will be more likely to be suscep-
tible to tamoxifen treatment. In immunohistochemistry,
the abundance of osteopontin may be more accurately
reflected in staining intensity than in percent positivity,
because the percentage of area stained is much more
susceptible to the placement of the section than is the
intensity, making the former a weaker readout. In a re-
lated setting, for ER in breast cancer, it has been shown
that the threshold of immunoreactivity is more import-
ant than the percentage positive in the generation of
discordant or false-negative assays [16].
The abundance of exon 4 is predictive of resistance to
chemotherapy with CMF, but not with AC/CMF. This
was initially surprising as osteopontin was not previously
known to convey resistance to methotrexate or fluorouracil.
In contrast, the two AC agents, doxorubicin (adriamycin)
and cyclophosphamide, have been reported to be subject to
osteopontin-mediated drug resistance. The finding may
point to translational limitations for testing drug sensitivity
with mono-therapy in cell culture, as was done in the pub-
lished resistance studies [1–4]. It may also be reflective of
the benefit conveyed with altering drug combinations over
treatment cycles, not only to alleviate toxicity but also to
enhance efficacy. By broadening and alternating the drug
regimen, the response to treatment in our breast cancer pa-
tients could be enhanced.
Fig. 3 Kaplan-Meier survival curves for patients undergoing
radiotherapy. Survival of patients under radiotherapy, distinguished
according to low (0–1, diamonds) versus high (2–3, triangles)
immunohistochemical markers. Shown are Kaplan Meier curves for
osteopontin-c (top panel) or exon 4 (middle panel). For comparison,
the survival of all patients receiving radiation (gray markers) or not
treated with radiation (black markers) is displayed (bottom panel).
The x-axis indicates years since diagnosis, the y-axis reflects %
surviving patients
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Table 5 Survival under specific treatments
Exon 4 intensity Exon 4 % OPN-c intensity OPN-c %
Treatment n Odds
ratio
















54 0.503 0.287-0.881 0.016 0.104 1.087 0.624-1.895 0.767 0.908 0.620 0.353-1.089 0.096 0.178 1.210 0.696-2.102 0.500 0.954
hormone yes
(all subgroups)
65 0.657 0.381-1.134 0.131 <.0001 0.687 0.391-1.206 0.191 0.056 0.826 0.463-1.473 0.517 0.005 1.101 0.630-1.923 0.735 0.704
hormone alone 18 1.534 0.430-5.467 0.509 0.614 1.122 0.420-2.998 0.819 0.616 1.661 0.607-4.542 0.323 0.518 1.113 0.383-3.235 0.845 0.607
hormone and
chemo
16 0.412 0.129-1.316 0.134 0.022 0.637 0.173-2.343 0.497 0.064 0.634 0.204-1.973 0.432 0.049 1.352 0.441-4.148 0.598 0.269
hormone and
radiation
10 0.358 0.069-1.862 0.222 0.180 0.495 0.096-2.558 0.401 0.568 0.250 0.029-2.180 0.209 0.185 0.827 0.192-3.561 0.798 0.597
hormone,
chemo, radiation
21 0.598 0.169-2.112 0.424 0.763 0.604 0.218-1.676 0.333 0.801 0.867 0.278-2.710 0.806 0.375 0.894 0.310-2.580 0.836 0.810
chemo no
(all subgroups)
30 0.711 0.320-1.580 0.403 0.025 0.794 0.366-1.722 0.560 0.233 0.903 0.391-2.084 0.811 0.134 0.978 0.425-2.254 0.959 0.612
chemo yes
(all subgroups)
89 0.582 0.371-0.913 0.019 0.001 0.873 0.552-1.383 0.564 0.520 0.694 0.439-1.098 0.119 0.003 1.181 0.754-1.848 0.468 0.327
chemo (CMF) 55 0.524 0.290- 0.943 0.031 0.008 0.727 0.403-1.314 0.291 0.693 0.706 0.391-1.276 0.249 0.013 1.113 0.626-1.979 0.715 0.337
chemo (AC/CMF) 34 0.688 0.338-1.400 0.302 0.144 1.252 0.596-2.632 0.553 0.543 0.681 0.329-1.410 0.301 0.121 1.280 0.608-2.694 0.515 0.727
chemo alone 13 0.418 0.111-1.574 0.197 0.763 1.207 0.367-3.971 0.757 0.637 0.711 0.205-2.468 0.592 0.047 1.200 0.362-3.980 0.766 0.560
chemo and
radiation
39 0.546 0.285-1.047 0.069 0.027 1.343 0.686-2.629 0.389 0.449 0.623 0.320-1.213 0.164 0.444 1.215 0.641-2.304 0.551 0.950
radiation no
(all subgroups)
47 0.647 0.333-1.259 0.200 0.024 0.973 0.519-1.824 0.933 0.203 0.981 0.527-1.826 0.951 0.105 1.400 0.746-2.627 0.294 0.404
radiation yes
(all subgroups)
72 0.626 0.376-1.044 0.073 0.002 0.774 0.466-1.285 0.321 0.489 0.675 0.394-1.157 0.153 0.036 1.086 0.659-1.791 0.745 0.832
Cox hazard ratios. The immunohistochemistry results for osteopontin-c and exon 4 were categorized into high staining (path scores 2 and 3) or low staining (path scores 0 and 1). Significant p-values are underlined,
and confidence intervals that do not contain 1.0 are shown in bold. The last column displays the p-value for the supremum test, which assesses the proportionality assumption. p-values in italics are significant and











Table 6 Survival under specific treatments
Exon 4 intensity Exon 4 % OPN-c intensity OPN-c %
Logrank Wilcoxon Logrank Wilcoxon Logrank Wilcoxon Logrank Wilcoxon
Treatment n χ2 p-value χ2 p-value χ2 p-value χ2 p-value χ2 p-value χ2 p-value χ2 p-value χ2 p-value
hormone no (all subgroups) 54 7.127 0.008 9.087 0.003 0.106 0.745 0.015 0.902 3.384 0.066 5.373 0.021 0.551 0.458 0.372 0.542
hormone yes (all subgroups) 65 2.631 0.105 6.981 0.008 1.970 0.160 3.267 0.071 0.480 0.489 2.218 0.136 0.130 0.719 0.140 0.708
hormone alone 18 0.591 0.442 0.226 0.635 0.069 0.793 0.071 0.790 1.303 0.254 0.961 0.327 0.050 0.823 0.184 0.668
hormone and chemo 16 2.613 0.106 3.937 0.047 0.531 0.466 1.071 0.301 0.707 0.401 1.778 0.182 0.317 0.573 0.101 0.751
hormone and radiation 10 1.833 0.176 2.709 0.100 0.837 0.360 0.987 0.320 2.049 0.152 2.485 0.115 0.075 0.784 0.011 0.915
hormone, chemo, radiation 21 0.703 0.402 0.601 0.438 1.036 0.309 1.139 0.286 0.065 0.799 0.240 0.624 0.047 0.829 0.089 0.765
chemo no (all subgroups) 30 0.833 0.361 3.472 0.062 0.403 0.526 1.123 0.289 0.067 0.795 0.465 0.495 0.003 0.955 0.049 0.825
chemo yes (all subgroups) 89 6.588 0.010 10.593 0.001 0.387 0.534 0.566 0.452 2.858 0.091 7.465 0.006 0.614 0.433 0.186 0.667
chemo (CMF) 55 5.455 0.020 9.345 0.002 1.275 0.259 1.561 0.212 1.522 0.217 4.847 0.028 0.152 0.697 0.016 0.899
chemo (AC/CMF) 34 1.289 0.256 1.608 0.205 0.420 0.517 0.317 0.574 1.300 0.254 2.740 0.098 0.507 0.477 0.456 0.500
chemo alone 13 1.865 0.172 1.268 0.260 0.107 0.743 0.245 0.620 0.322 0.570 1.356 0.244 0.099 0.753 0.126 0.722
chemo and radiation 39 4.123 0.042 8.229 0.004 0.898 0.344 0.209 0.648 2.380 0.123 3.271 0.071 0.431 0.512 0.180 0.672
radiation no (all subgroups) 47 1.964 0.161 3.638 0.057 0.009 0.927 0.067 0.796 0.005 0.946 0.497 0.481 1.310 0.252 1.819 0.178
radiation yes (all subgroups) 72 3.786 0.052 8.444 0.004 1.143 0.285 1.690 0.194 2.395 0.122 4.766 0.029 0.122 0.727 0.090 0.764











Discrepancies between this study and previous reports
that had indicated an association between osteopontin
levels and radiation resistance require an explanation.
We see three likely causes. a) While the regimens
tested here had overlap with the ones earlier associ-
ated with resistance, the treatments were complex and
included components that may have helped to over-
come resistance. Most patients in this study received
radiation in conjunction with hormone therapy and/or
chemotherapy. b) Overall, the efficacies of radiation
treatment were low, reflected in poor survival in the
treated groups. The underlying reason is that more ag-
gressive treatment is given to patients with worse
prognosis and could be interpreted to mean that all
patients receiving radiation were in essence resistant.
Therefore, no differences were discernible between the
marker (osteopontin-c or exon 4) high and low groups. c)
It is possible that the observations of this study may be
compromised by its moderate power (119 patients). We
previously reported that osteopontin-c is correlated to
tumor grade [13] and the combination of both readouts
slightly improves the prediction of survival [8]. In the
present study, no correlation was identified between
osteopontin-c and tumor grade or exon 4 and tumor
grade, which may be attributable to the limited group
size. The lack of significance for predicting survival by
dichotomized osteopontin-c in the logrank test might
seem to support this possibility.
Table 7 Multivariate analysis
Hazard ratios and p-values for survival under hormone therapy, using exon 4 staining (0–1 = low, 2–3 = high) or osteopontin-c staining (0–1 = low, 2–3 = high) plus
other readouts as covariates. The combination of exon 4 intensity plus grade, which strengthens the prediction compared to exon 4 intensity alone, is boxed
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Beside breast cancer, pan-osteopontin levels have been
associated with treatment responses of prostate cancer
to taxanes/androgen deprivation [17], of lung cancer
(NSCLC) to carboplatin/paclitaxel [18], and of colorectal
cancer to FOLFIRI-bevacizumab [19] (as osteopontin in-
teracts with VEGF in multiple ways [20] it would be ex-
pected to affect the response to bevacizumab). In some
of the predecessor studies, however, it has not been clear
whether osteopontin was functionally linked to a re-
duced treatment response or independently predicted
poor survival, because tumors with higher levels of the
biomarker are more aggressive and inherently have a bad
prognosis. A mechanistic connection of pan-osteopontin
to drug resistance was established in prostate cancer.
Osteopontin binds to integrin αvβ3 and concentration-
and time-dependently upregulates the efflux transporter
ABCB1 (P-glycoprotein, PGP), which causes resistance to
drugs that are substrates for this transporter [21]. Similarly
in breast tumor cells, osteopontin may activate the hedge-
hog pathway and enhance drug resistance through GLI1-
dependent regulation of ABCB1 and ABCG2 [4].
Conclusions
In conclusion, immunohistochemistry of osteopontin splice
variants has potential to aid decision making in breast can-
cer treatment. Specifically, osteopontin exon 4 is associated
with a favorable response to tamoxifen, but a poor re-
sponse to chemotherapy with CMF (cyclophosphamide,
methotrexate, fluorouracil). While being prognostic,
osteopontin-c may not be a significant predictor for sensi-
tivity to treatment.
Abbreviations
AC, cyclophosphamide, doxorubicin; AIC, Aikaike information criterion; CMF,
cyclophosphamide, methotrexate, fluorouracil; ER, estrogen receptor; OPN,
osteopontin; PR, progesterone receptor; sem, standard error of the mean;
Std, standard deviation
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